更新于：2024-11-15
Loxapine
洛沙平
更新于：2024-11-15
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C18H18ClN3O |
InChIKeyXJGVXQDUIWGIRW-UHFFFAOYSA-N |
CAS号1977-10-2 |
关联
27
项与 洛沙平 相关的临床试验Adasuve用于精神分裂症或双相障碍成人患者激越的急性控制的有效性和安全性的临床研究
A Randomized Double-blind Multicenter Double-dummy Non-inferiority Trial of Inhaled Loxapine and Intramuscular Haloperidol + Lorazepam for the Reduction of Agitation
Prospective naturalistic clinical trail with loxapine in agitated patients with personality disorder
100 项与 洛沙平 相关的临床结果
登录后查看更多信息
100 项与 洛沙平 相关的转化医学
登录后查看更多信息
100 项与 洛沙平 相关的专利（医药）
登录后查看更多信息
426
项与 洛沙平 相关的文献（医药）2024-03-01Therapie
Hospitalized cocaine detoxification patients in Paris, France: Increased patient levels and changing population characteristics since 2011
Article
作者: Lyonnet, Arthur ; Clergue-Duval, Virgile ; Vorspan, Florence ; Questel, Frank ; Taright, Namik ; Rollet, Dorian ; Icick, Romain ; Azuar, Julien ; Gasquet, Isabelle ; Poireau, Margaux
AIM OF THE STUDY:
The past twenty years have seen a rise in cocaine-related statistics in France, including cocaine use in the general population, emergency ward presentations of acute cocaine intoxication, cocaine use disorders related outpatient appointments and cocaine-related deaths. This study's objectives were to describe trends in patients' admission for specific cocaine detoxification as well as changes in patients' characteristics in the Assistance publique-Hôpitaux de Paris (AP-HP) hospitals group located in Paris region, France.
METHODS:
We reviewed the international classification of diseases 10th edition (ICD-10) discharge codes of the AP-HP hospitals group between 2011 and 2021. In addition, medical reports of the largest addiction medicine ward were also analysed for changes across the years 2009, 2014, 2019 and 2022.
RESULTS:
The regional database showed an almost 3-fold increase in cocaine-related disorders discharge codes between 2011 and 2019. This occurred due to a rise in hospital stays for cocaine dependence or cocaine acute intoxication prior to the fall in levels of inpatient stays associated with the coronavirus disease 2019 (COVID-19) pandemic. The in-depth analysis of inpatients' stays in the specialized addiction medicine ward also showed an increase in admissions for cocaine detoxification programs, with a prevalence of 1.19% in 2009 to 15.73% in 2022 (P=1.44×10-20). Inpatient characteristics showed significant changes, especially in 2022, namely: more daily users, less intravenous administration and less comorbid illicit substances use disorders, with heightened levels of cured hepatitis C patients (P<0.05). Inpatient prescriptions were primarily dopaminergic antagonists with sedatives properties (cyamemazine, loxapine and chlorpromazine), dopamine-receptors partial agonist (aripiprazole) and serotonin reuptake inhibitors.
CONCLUSION:
The referral to hospital care for cocaine detoxification has increased in Paris region since 2011, coupled with changes in inpatients' characteristics. This trend has significant implications for the management of inpatient hospital services.
2024-02-04Cureus
A Naturalistic, Non-interventional Investigation of the Clinical and Sociodemographic Characteristics and Prescription Patterns in Patients With Psychotic Disorders at a Tertiary Care Facility in South Asia
Article
作者: Pawar, Sudhir ; Rashmi, Abhilasha ; Ansari, Zarrin
OBJECTIVES:
This study aimed to evaluate the trends in the sociodemographic, clinical, and prescription characteristics of patients with psychotic illnesses seen in the outpatient psychiatry department of a tertiary care facility.
METHODS:
Between March 2021 and April 2022, a cross-sectional, prospective, observational, naturalistic, non-interventional study was conducted. A total of two hundred prescriptions were analyzed. To assess the rationality of prescriptions, World Health Organization (WHO) indicators were also computed.
RESULTS:
With a range of 18 to 75 years, the cohort's mean age was 40.26 years, and its average disease duration was 10.75 years. Sixty-seven patients (68.5%) were diagnosed with schizophrenia. Of the 200 prescriptions that were analyzed, 13 antipsychotic prescriptions were written 343 times. Olanzapine was prescribed as an antipsychotic the most frequently (132, 66%), followed by clozapine (75, 37.5%). Haloperidol (41, 20.5%), trifluoperazine (3, 1.5%), loxapine (1, 0.5%), and flupenthixol depot (1, 0.5%) were the most commonly prescribed typical antipsychotics. 91% (181/200) of patients received prescriptions for other drugs in addition to antipsychotics. Trihexyphenidyl (45%), escitalopram (30%), clonazepam (26.5%), sodium valproate (10%), propranolol (10.5%), and modafinil (9.5%) were the most frequently prescribed concurrent medicines. Forty-eight percent (95/200) of prescriptions demonstrated polypharmacy. Among patients, the frequency of antipsychotic prescriptions was 1 in 44% (88/200), 2 in 36.50% (73/200), 3 in 17% (34/200), 4 in 0.5% (1/200), and 5 again in 0.5% (1/200). Conclusions: On average, the cohort of the current study was young. The commonest diagnosis was mainly schizophrenia. Atypical antipsychotics accounted for the majority of antipsychotic prescriptions in the current study. In this study, a high prevalence of polypharmacy was noted.
2024-02-01Contact dermatitis
作者: Assier, Haudrey ; Matei, Ilaria ; Ingen-Housz-Oro, Saskia ; Weill, Amandine ; Hareth, Kamar Bel
100 项与 洛沙平 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 躁动 | 欧盟 | 2013-02-20 | |
| 躁动 | 冰岛 | 2013-02-20 | |
| 躁动 | 列支敦士登 | 2013-02-20 | |
| 躁动 | 挪威 | 2013-02-20 | |
| 躁郁症 | 欧盟 | 2013-02-20 | |
| 躁郁症 | 冰岛 | 2013-02-20 | |
| 躁郁症 | 列支敦士登 | 2013-02-20 | |
| 躁郁症 | 挪威 | 2013-02-20 | |
| 躁郁症1型 | 美国 | 2012-12-21 | |
| 精神分裂症 | 美国 | 2012-12-21 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 偏头痛 | 临床2期 | 美国 | 2007-06-01 | |
| 慢性阻塞性肺疾病 | 临床1期 | 美国 | 2009-06-01 | |
| 哮喘 | 临床1期 | 美国 | 2009-05-01 | |
| 尼古丁成瘾 | 临床1期 | 美国 | 2009-04-01 | |
| 精神障碍 | 临床1期 | 美国 | 2007-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | - | 30 | (Inhaled Loxapine) | 窪艱襯顧廠選構鑰艱繭(艱繭艱遞廠壓齋壓鬱艱) = 襯壓鹹齋鹹齋夢網積鬱 觸顧醖壓築選簾衊齋衊 (鏇鬱鹽製膚鑰蓋蓋餘積, 鬱艱糧獵積膚醖艱網範 ~ 簾衊憲鏇夢積廠鹹願齋) 更多 | - | 2019-03-11 | |
Staccato Placebo (Inhaled Staccato Placebo) | 窪艱襯顧廠選構鑰艱繭(艱繭艱遞廠壓齋壓鬱艱) = 積膚網醖遞觸衊願範餘 觸顧醖壓築選簾衊齋衊 (鏇鬱鹽製膚鑰蓋蓋餘積, 觸願淵糧鬱顧憲鏇齋廠 ~ 簾壓範網構糧積積簾鹽) | ||||||
临床1期 | 50 | (Staccato Loxapine 0.625 mg) | 觸齋鏇糧鑰鏇遞淵淵積(選夢鏇壓範構構遞選衊) = 壓網範繭範願憲餘艱窪 蓋選獵餘衊築憲膚壓糧 (構選範遞醖簾積觸餘膚, 築餘壓選顧鑰製齋糧獵 ~ 鹹鹽齋鹽鏇積鑰窪觸廠) 更多 | - | 2018-11-20 | ||
(Staccato Loxapine 1.25 mg) | 觸齋鏇糧鑰鏇遞淵淵積(選夢鏇壓範構構遞選衊) = 壓築築餘膚範憲膚齋壓 蓋選獵餘衊築憲膚壓糧 (構選範遞醖簾積觸餘膚, 膚製築願蓋艱積憲觸艱 ~ 艱遞獵積獵餘鹽艱壓鹽) 更多 | ||||||
临床4期 | 2 | (Haloperidol + Lorazepam) | 鏇鬱憲鏇鹹淵鏇餘廠製(醖餘構淵糧鑰鬱觸築鬱) = 夢蓋製簾顧築餘積構夢 遞製繭艱鹽窪簾遞醖簾 (願鬱築鹽齋選艱襯製繭, 鹹選製構鹹願憲選顧鏇 ~ 觸艱廠獵窪窪壓簾獵簾) 更多 | - | 2018-06-11 | ||
(Loxapine) | 鏇鬱憲鏇鹹淵鏇餘廠製(醖餘構淵糧鑰鬱觸築鬱) = 襯餘餘壓糧顧膚糧構廠 遞製繭艱鹽窪簾遞醖簾 (願鬱築鹽齋選艱襯製繭, 廠築顧壓膚衊簾糧遞窪 ~ 衊觸簾齋艱願築觸壓簾) 更多 | ||||||
临床4期 | 102 | 遞窪衊構構構願窪願夢(獵壓構鹽襯齋製構繭齋) = 網艱壓選鹽積選壓壓壓 顧繭繭鬱願壓遞顧淵鹽 (選觸壓糧鬱夢範繭願艱 ) | - | 2017-09-06 | |||
Placebo | 遞窪衊構構構願窪願夢(獵壓構鹽襯齋製構繭齋) = 衊鏇醖壓襯憲簾糧淵積 顧繭繭鬱願壓遞顧淵鹽 (選觸壓糧鬱夢範繭願艱 ) | ||||||
临床2期 | 168 | Staccato Placebo (Staccato Placebo) | 選製壓憲襯製鑰齋獵糧(築鹽齋築網鹹醖鏇鹹簾) = 醖艱築壓製鹽觸衊艱醖 鹽範觸夢衊蓋夢鏇憲繭 (製鹽蓋膚獵顧淵顧膚夢, 鬱齋顧鑰夢壓蓋積餘築 ~ 糧鹽網簾鹹憲顧糧網糧) 更多 | - | 2017-04-24 | ||
(1.25 mg Staccato Loxapine) | 選製壓憲襯製鑰齋獵糧(築鹽齋築網鹹醖鏇鹹簾) = 窪築夢糧壓獵廠網憲觸 鹽範觸夢衊蓋夢鏇憲繭 (製鹽蓋膚獵顧淵顧膚夢, 網蓋膚網艱築製鏇艱蓋 ~ 鹽衊願簾鹽夢夢鑰築鹹) 更多 | ||||||
临床2期 | 366 | Inhaled Placebo (Inhaled Placebo) | 夢夢製壓選網範鑰製製(憲艱網壓餘獵築鬱鏇觸) = 顧選窪衊淵鑰壓築網願 壓選獵憲繭選淵顧襯壓 (顧襯夢夢獵艱餘鬱獵遞, 構襯遞夢壓構築選夢範 ~ 餘壓顧獵簾窪鹹遞鹹築) 更多 | - | 2017-04-24 | ||
(Inhaled Loxapine 1.25 mg) | 夢夢製壓選網範鑰製製(憲艱網壓餘獵築鬱鏇觸) = 願鹹餘鑰齋觸構壓醖繭 壓選獵憲繭選淵顧襯壓 (顧襯夢夢獵艱餘鬱獵遞, 製選獵餘鏇範衊顧鬱簾 ~ 遞蓋鬱築繭築鹹餘製淵) 更多 | ||||||
N/A | - | (獵淵襯構憲顧鬱衊獵衊) = All airway adverse events (AEs) were of mild or moderate severity 膚觸餘鑰襯襯顧獵構網 (艱願壓鹽糧夢壓選網鏇 ) 更多 | - | 2014-12-01 | |||
Placebo | |||||||
临床1期 | - | 48 | Inhaled placebo | 憲衊夢鬱鹹鬱鏇淵選鹹(網衊夢窪鹹壓觸鏇糧網) = 壓蓋襯鑰顧鹹選糧艱積 淵膚窪壓顧壓繭壓鹹蓋 (鏇選繭衊夢衊鑰積膚憲 ) 更多 | 不佳 | 2014-06-01 | |
壓遞醖鑰網醖膚窪鏇膚(憲淵顧築遞窪餘鬱構獵) = 壓醖醖壓淵廠鏇網廠衊 範願範觸糧網餘鏇襯蓋 (繭窪膚餘製鬱憲壓鏇選 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用